Open AccessPartial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
Author(s) -
Gunther Jillian R.,
Pinnix Chelsea C.,
Glober Gordon R.,
Christopherson Kaitlin M.,
Fang Penny,
Lee Hun Ju,
Ahmed Sairah,
Steiner Raphael E.,
Nair Ranjit,
Strati Paolo,
Neelapu Sattva S.,
Nastoupil Loretta J.,
Dabaja Bouthaina S.
Publication year - 2020
Publication title -
ejhaem
Language(s) - English
Resource type - Journals
ISSN - 2688-6146
DOI - 10.1002/jha2.1
Subject(s) - abvd , bleomycin , dacarbazine , vinblastine , medicine , stage (stratigraphy) , regimen , oncology , lymphoma , hodgkin's lymphoma , surgery , chemotherapy , vincristine , cyclophosphamide , paleontology , biology
Classical Hodgkin lymphoma (HL) patients achieve excellent outcomes; therefore, treatment de‐escalation strategies to spare toxicity have been prioritized. In a large randomized trial of early‐stage HL patients, omission of chemotherapeutic agents including bleomycin from the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen was not found to be noninferior; however, the effect of partial omission is unknown. We investigated the effect of bleomycin omission on outcome for 150 early‐stage HL patients. At 8 years, freedom from relapse was 99% for both patients who received complete or incomplete bleomycin, which is reassuring for patients requiring bleomycin omission due to toxicity.